Wegovy® pill delivered 21.6% weight loss in early responders and doubled mobility improvement, according to new Novo Nordisk data at ECO2026

Almost a third of adults taking Wegovy® pill (oral semaglutide 25 mg) were early responders to treatment, achieving an average of 13.2% weight loss after four months and 21.6% weight loss at the end of the OASIS 4 clinical trial1. Nearly eight in 10 people with poor physical function who took the Wegovy® pill almost doubled their ability to move, including bending over, standing comfortably and staying active, compared to placebo2.